ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1083

Glomerular Staining and Serum Antibodies of THSD7A in Malignancy-Associated Membranous Nephropathy

Session Information

Category: Pathology and Lab Medicine

  • 1502 Pathology and Lab Medicine: Clinical

Authors

  • Zhang, Changming, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
  • Zhang, Ming-chao, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
  • Chen, Da cheng, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China, Nanjing, China
  • Ren, Qiang, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
  • Xu, Weiwei, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
  • Qin, Wei-song, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
  • Liu, Zhihong, National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, China
Background

Thrombospondin type 1 domain-containing 7A (THSD7A) is recently identified as the target antigen in patients with membranous nephropathy (MN). A notable phenomenon is the high rate of cancer (reported to be as high as 20%) in patients with THSD7A-associated MN. The prevalence of THSD7A in patients with malignancy-associated MN deserves further clarification.

Methods

Glomerular expression of THSD7A was examined by immunohistochemistry in 36 patients with malignancy-associated MN. Immunofluorescence assay was performed to investigate anti-THSD7A antibodies. Anti-PLA2R antibodies and glomerular PLA2R expression was also screened. THSD7A expression of cancer tissues was tested in 9 among the 36 patients.

Results

Among the 36 patients with malignancy-associated MN, 3 (8.3%) patients were identified as glomerular THSD7A staining positive: one patient was THSD7A positive alone, which accounted for 6.3% (one of 16) of PLA2R negative patients; two patients were dual-positive for both THSD7A and PLA2R staining. No anti-THSD7A antibody was detected among the 36 patients, whereas 18 of 36 (50%) had anti-PLA2R antibodies. Among the 9 patients who were available for cancer THSD7A staining, five (56%) patients showed enhanced expression of THSD7A localized in cancer tissue: one patient also had enhanced expression of THSD7A in glomeruli.

Conclusion

We found that positive glomerular THSD7A staining was uncommon in patiens with malignancy-associated MN.